2,2-联苯基丙基胺盐酸盐 | 40691-66-5

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,2-联苯基丙基胺盐酸盐
• 中文别名: 2,2-二苯基丙胺盐酸盐
• 英文名称: 2,2-diphenyl-propylamine; hydrochloride
• 英文别名: 2,2-Diphenyl-propylamin; Hydrochlorid；β-methyl-β-phenylphenethylamine hydrochloride；2,2-diphenylpropylamine hydrochloride；2,2-Diphenylpropan-1-amine;hydron;chloride；2,2-diphenylpropan-1-amine;hydron;chloride
• CAS: 40691-66-5
• 化学式: C₁₅H₁₇N*ClH
• mdl: MFCD00008133
• 分子量: 247.768
• InChiKey: AASCJSPDUDWGGQ-UHFFFAOYSA-N

物化性质

• 熔点：
  250-256°C
• 稳定性/保质期：

  常规情况下不会分解，也没有危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.26
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38

SDS

Name:	2 2-Diphenylpropylamine Hydrochloride 95% Material Safety Data Sheet
Synonym:
CAS:	40691-66-5

Section 1 - Chemical Product MSDS Name:2 2-Diphenylpropylamine Hydrochloride 95% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
40691-66-5	2,2-Diphenylpropylamine Hydrochloride	95	255-039-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use only in a well-ventilated area.
Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 40691-66-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 248.00 - 255.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H17N.HCl
Molecular Weight: 247.77

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 40691-66-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,2-Diphenylpropylamine Hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 40691-66-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 40691-66-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 40691-66-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,2-联苯基丙基胺盐酸盐 、 6-氯嘌呤核苷 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N6-(2,2-diphenylpropyl)adenosine
  参考文献：
  名称：

  N.sup.6 -substituted adenosines for treating pain

  摘要：

  N.sup.6-取代的二芳基烷基腺苷及其具有极具吸引力的中枢神经系统和心血管特性的药用可接受的酸盐，描述了其制造过程和药用组合物以及使用所述化合物和组合物的方法。

  公开号：

  US04657897A1

文献信息

• N.sup.6 -substituted adenosines and method of use
  申请人：Warner-Lambert Company

  公开号：US04657898A1

  公开（公告）日：1987-04-14

  N.sup.6 -Substituted diarylalkyladenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are described.

  本文描述了N.sup.6-取代二芳基烷基腺苷及其药学上可接受的酸盐，具有高度理想的中枢神经系统和心血管特性，以及制造这些化合物的过程和制药组合物，以及使用这些化合物和组合物的方法。
• Thromboresistant materials incorporating pyrazinone protease inhibitors
  申请人：——

  公开号：US20010021713A1

  公开（公告）日：2001-09-13

  Thromboresistant materials are described which incorporate pyrazinone compounds of the Formula I: 1 wherein X is O, NR 11 or CH=N, R 3 -R 11 , R a , R b , R c , W, m, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

  本发明提供了一种含有Formula I的吡唑酮化合物的抗血栓材料：1其中X为O、NR11或CH= N，R3-R11、Ra、Rb、Rc、W、m和n在规范中设置，以及其水合物、溶剂化合物或药学上可接受的盐。本发明的化合物是蛋白酶的强效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶、血纤维蛋白溶解酶和Xa因子。其中某些化合物通过直接、选择性地抑制凝血酶表现出抗血栓活性。本发明还描述了用于抑制血小板损失、抑制血小板聚集、抑制纤维蛋白形成、抑制血栓形成和抑制栓子形成的组合物。本发明的化合物的其他用途是作为抗凝剂嵌入或物理链接到用于血液收集、血液循环和血液储存的设备中，如导管、血液透析机、血液采集注射器和管道、血管支架等。此外，这些化合物可以被检测标记并用于体内血栓的成像。
• N6-substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0139358A2

  公开（公告）日：1985-05-02

  N6 -Substittuted diarylalkyladenosines of the formula: are disclosed. Processes for their manufacture and pharmaceutical compositions containing the same are also disclosed. The compounds have highly desirable central- nervous system and cardio-vascular properties.

  式中的 N6-取代二芳基烷基腺苷： 的二芳基烷基腺苷。还公开了其制造工艺和含有这些化合物的药物组合物。这些化合物具有非常理想的中枢神经系统和心血管特性。
• N6- substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0251339A2

  公开（公告）日：1988-01-07

  N⁶-Substituted diarylalkyladenosines of the formula: are disclosed. Processes for their manufacture and pharmaceutical compositions containing the same are also disclosed. The compounds have highly desirable central-nervous system and cardio-vascular properties.

  本发明公开了式：的 N⁶-取代二芳基烷基腺苷，还公开了其生产工艺和含有这些化合物的药物组合物。 这些化合物具有非常理想的中枢神经系统和心血管特性。
• Levy; Gallais, Bulletin de la Societe Chimique de France, 1928, vol. <4> 43, p. 865
  作者：Levy、Gallais

  DOI：——

  日期：——

表征谱图